Formycon AG (ETR:FYB)
22.70
-1.05 (-4.42%)
Mar 31, 2025, 2:38 PM CET
Formycon AG Revenue
In the year 2024, Formycon AG had annual revenue of 69.67M EUR, down -10.32%. Formycon AG had revenue of 26.89M in the half year ending June 30, 2024, with 52.42% growth.
Revenue
69.67M
Revenue Growth
-10.32%
P/S Ratio
5.96
Revenue / Employee
291.52K
Employees
238
Market Cap
419.35M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Formycon AG News
- 4 days ago - Formycon's 2024: Financial Success & Market Growth - Wallstreet:Online
- 4 days ago - EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position - Wallstreet:Online
- 7 days ago - EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 - Wallstreet:Online
- 4 weeks ago - EQS-News: FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the United States and the European Union - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea, under the brand name AHZANTIVE - Wallstreet:Online
- 5 weeks ago - EQS-DD: Formycon AG: Dr. Andreas Seidl, buy - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin - Wallstreet:Online
- 6 weeks ago - Formycon AG: Biosimilar Updates & Conference Call Invite - Wallstreet:Online